Microangiopathic antiphospholipid antibody syndrome due to anti-phosphatidylserine/prothrombin complex IgM antibody

Pediatr Int. 2017 Mar;59(3):378-380. doi: 10.1111/ped.13224.

Abstract

Herein we describe a case of microangiopathic antiphospholipid syndrome (MAPS) due to anti-phosphatidylserine/prothrombin complex (aPS/PT) IgM antibody successfully treated with rituximab. A significant correlation was observed between the clinical course and the aPS/PT IgM antibody titer, which can rise earlier before the appearance of clinical symptoms. Rituximab can be safely and effectively used for MAPS. Although detection of only aPS/PT IgM antibody is rare, aPS/PT IgM antibody might be associated with the pathogenesis of MAPS and might be a useful marker of disease activity.

Keywords: anti-phosphatidylserine/prothrombin complex IgM antibody; microangiopathic antiphospholipid antibody syndrome; rituximab.

Publication types

  • Case Reports

MeSH terms

  • Antiphospholipid Syndrome / blood
  • Antiphospholipid Syndrome / diagnosis
  • Antiphospholipid Syndrome / drug therapy
  • Antiphospholipid Syndrome / immunology*
  • Autoantibodies / blood*
  • Biomarkers / blood
  • Child
  • Female
  • Humans
  • Immunoglobulin M / blood*
  • Immunologic Factors / therapeutic use*
  • Phosphatidylserines / immunology*
  • Prothrombin / immunology*
  • Rituximab / therapeutic use*

Substances

  • Autoantibodies
  • Biomarkers
  • Immunoglobulin M
  • Immunologic Factors
  • Phosphatidylserines
  • Rituximab
  • Prothrombin